Standard BioTools Inc
NASDAQ:LAB

Watchlist Manager
Standard BioTools Inc Logo
Standard BioTools Inc
NASDAQ:LAB
Watchlist
Price: 1.71 USD 5.56% Market Closed
Market Cap: 636.6m USD
Have any thoughts about
Standard BioTools Inc?
Write Note

Standard BioTools Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Standard BioTools Inc
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Standard BioTools Inc
NASDAQ:LAB
Total Current Liabilities
$123.8m
CAGR 3-Years
33%
CAGR 5-Years
27%
CAGR 10-Years
16%
Thermo Fisher Scientific Inc
NYSE:TMO
Total Current Liabilities
$14.6B
CAGR 3-Years
23%
CAGR 5-Years
20%
CAGR 10-Years
9%
Danaher Corp
NYSE:DHR
Total Current Liabilities
$7.3B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
5%
Mettler-Toledo International Inc
NYSE:MTD
Total Current Liabilities
$1.2B
CAGR 3-Years
6%
CAGR 5-Years
10%
CAGR 10-Years
6%
Agilent Technologies Inc
NYSE:A
Total Current Liabilities
$2.4B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
4%
IQVIA Holdings Inc
NYSE:IQV
Total Current Liabilities
$7B
CAGR 3-Years
13%
CAGR 5-Years
14%
CAGR 10-Years
17%
No Stocks Found

Standard BioTools Inc
Glance View

Market Cap
632.6m USD
Industry
Life Sciences Tools & Services

Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.

LAB Intrinsic Value
1.09 USD
Overvaluation 36%
Intrinsic Value
Price

See Also

What is Standard BioTools Inc's Total Current Liabilities?
Total Current Liabilities
123.8m USD

Based on the financial report for Jun 30, 2024, Standard BioTools Inc's Total Current Liabilities amounts to 123.8m USD.

What is Standard BioTools Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
16%

Over the last year, the Total Current Liabilities growth was 165%. The average annual Total Current Liabilities growth rates for Standard BioTools Inc have been 33% over the past three years , 27% over the past five years , and 16% over the past ten years .

Back to Top